Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female engineer named Morgan Beller.Technologyread more
CoinShares Chief Strategy Officer Meltem Demirors discusses Facebook's Libra project and its impact on the cryptocurrency market after testifying to the House Financial...Fast Moneyread more
After a year of flooding, Midwest farmers face a stifling heat wave that's spreading across the U.S.Agricultureread more
Iran's Revolutionary Guard claims a British tanker it still holds, Stena Impero, failed to follow international maritime rules.World Newsread more
Moving lots of data to a public cloud over the internet can take months or years. CNBC got an inside look at how AWS transfers data to the cloud for its clients.Technologyread more
A quarter of the S&P 500 companies report earnings next week, and that could buffet the market as investors await the July Fed meeting.Market Insiderread more
Some 40% of Americans would struggle to come up with even $400 to pay for an emergency expense. Just how are so many Americans so short on cash? Blame debt.Personal Financeread more
Amazon hires Trump-allied lobbyist Jeff Miller as battle for Pentagon contract heats up.Politicsread more
In a series of tweets, the president addressed an unusual controversy stemming from a speech delivered Thursday by New York Fed President John Williams.Marketsread more
"You need to understand that we're about to embark on the busiest week of the year for industrial earnings," CNBC's Jim Cramer says.Mad Money with Jim Cramerread more
Boston Federal Reserve President Eric Rosengren is lining up against an apparent push to cut interest rates, telling CNBC in an interview Friday that the central bank can...The Fedread more
Believe it or not, when "Mad Money" first came on the air a decade ago, Cramer had a hard time getting executives to appear on the show.
The very first CEO interview was with Dr. Len Schleifer, who was at the time the CEO of a small development stage biotech company called Regeneron.
At the time the stock traded just above $4, and as of Monday it closed at $426. Cramer gave this stock his blessing for speculation, and the company turned out to be one of the best blessings he has ever given. Its cholesterol drug has been a big hit, and Cramer thinks it could bring the stock even higher.
Could the company foresee that it would be so profitable? Cramer sat down with Dr. Schleifer 10 years later to find out.
"The thing about this business is that it's all based on what you do for patients. This is not the soap business or the detergent business where the marketing clout matters. The bottom line is if you come out with a product that makes a difference for patients you're going to sell the product, patients are going to do better and your investors and shareholders are going to profit as well," Schleifer said.
Read more from Mad Money with Jim Cramer
Cramer: The Fed still knows nothing
Cramer: Relax! Here's how to deal with the decline
Ford CEO: Strong dollar? No problem
The CEO elaborated that when Regeneron first began, it took a big risk with not a lot of support.
"We thought that if we just stuck with the science we could get there. We didn't know how long it would take, and didn't have a lot of people who believed in us," Schleifer added.
Cramer is one of those people who believed in the stock, which has increased more than ten fold since inception. He still considers it to be one one of his top biotech stocks.